ST. LOUIS, Nov. 24 /PRNewswire/ -- A study released recently in the
British Journal of Urology detailed the results from biopsies of 140 men who
received care at Washington University in St. Louis, Duke University, and the
University of Michigan. The study, titled "Evaluation of a novel precision
template-guided biopsy system for detecting prostate cancer," found that
TargetScan(R) template guided biopsy technology potentially produces a higher
cancer detection rate and more accurate assessment of grade.
The TargetScan system combines 3-D image acquisition with a stationary
probe, which helps physicians plan and execute targeted prostate biopsies
through accurate needle placement within a template, which in turn, can
provide confidence in identifying locations of significant cancer in the
"As physicians we are challenged to provide accurate diagnosis and define
the true extent of the disease so we don't over or underestimate the
significance of the cancer," said Dr. Gerald Andriole, Professor and Chief of
Urology at Washington University in St Louis School of Medicine, a member of
the multi-center team that conducted the evaluation of TargetScan. The study's
lead author, Dr. Adam Kibel, also from Washington University, agrees. "This
technology allows physicians to accurately biopsy the prostate since the
location of each biopsy is calculated on the basis of the prostate's size and
shape. This may allow us to more accurately find and define the disease. This
may allow better monitoring of patients on active surveillance. Importantly,
since the location of each biopsy site is recorded, re-biopsy or treatments
can be performed with more precision."
TargetScan Touch(TM) is the most current system based on the TargetScan
technology platform. TargetScan Touch was unveiled recently at the 2008
American Society for Therapeutic Radiology and Oncology annual meeting, and
has been tested at several of the nation's leading medical centers.
TargetScan technology is developed by Envisioneering Medical Technologies
in St. Louis, under the guidance of physicians at Washington University in St.
Louis. "Traditional hand-manipulated devices allow the prostate gland to
shift, which impedes accurate biopsy and placement accuracy. By stabilizing
the prostate, physicians can now detect cancer with greater confidence," said
Robert Mills, president, Envisioneering Medical Technologies.
About Envisioneering Medical Technologies
Envisioneering Medical Technologies, based in St. Louis, Mo., is dedicated
to creating the standard for prostate cancer care by developing technology for
improving prostate cancer diagnosis and treatment precision and effectively
managing patients throughout the continuum of care. For more information
please visit http://www.envisioneeringmedical.com.
Related medicine news :1
|SOURCE Envisioneering Medical Technologies|
Copyright©2008 PR Newswire.
All rights reserved
. Bartlett Communications Launches Free Website Evaluation Tool for Small to Mid-Sized Businesses2
. Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures3
. Best Practice Database Provides Key Findings for Biopharma Product Launch Evaluation4
. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter5
. VA Announces Expansion of Disability Evaluation System Pilot6
. DIA/FDA/PhRMA Drug Safety Conference: Planning the Lifecycle of Safety Evaluation 7
. Study sees need for standardized evaluation of antibody response to HIV-18
. Hooper Holmes Announces Sale of Claims Evaluation Division9
. Syntermed licenses Emory imaging technology for improved evaluation of heart failure patients10
. Dartmouth-Hitchcock Medical Center Evaluation Findings Demonstrate Masimo Patient SafetyNet(TM) Delivers Improvements in Clinical Outcomes and Patient Safety on General Care Floors11
. Population Health Impact Institute Releases Methods Evaluation Process(TM) (MEP(TM)) Accreditation Standards for Public Comment Period